DXVX Stock: price and insider trades · South Korea

DXVX is a Health Care company. Its directors and officers file their transactions with DART (FSS). In the past year (18 October 2025 to 18 October 2026), 23 filings came from 7 insiders.

Purchases and sales both appear in the filings: 21 purchases (6 insiders, €1.3M) and 1 sale (1 insider). The totals do not cover 16 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €671k, bought by 임종윤 and made public on 7 April 2026 (0.41% of market cap). Among those who bought: 3 board members, 1 major shareholder and 1 chief executive.

The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 1 October 2026, 17 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 7 days. That lag is the time during which only the insider knows about the trade.

Across the 2,629 companies tracked on its exchange, the median is 7 filings; at 23 filings, this issuer sits above that mark. Our records for DXVX go back to 2021, with 62 purchases and 20 sales on the open market in total.

In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.